Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

In some ways, pharma connecting directly with patients isn’t novel at all: pharma companies in the United States have been ...

This kind of voluntary information that customers share directly with advertisers is known as zero-party data – and it has ...

Dr Marks formally resigned from his post on 28th March and is due to step down on 5th April, and his resignation letter ...